Clinical Trial Update: Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016) [Phase 1]

View source ↗

Summary

Phase I study of dalotuzumab in combination with cetuximab and irinotecan in colorectal cancer completed; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• Dalotuzumab (dalotuzumab)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Colorectal Cancer | Phase 1 | Status: COMPLETED | Results posted: 2017-08-02